Monday, 19 October 2026European Markets

NYXOAH Stock Over 31% Up In The Last 21 Sessions

Loading stream...

(VIANEWS) - Shares of NYXOAH (BEL 20: NYXH.BR) jumped by a staggering 31.53% in 21 sessions from €5.17 to €6.80 at 14:43 EST on Friday, following the last session's upward trend. BEL 20 is jumping 0.99% to €3,807.06, after two successive sessions in a row of gains.

NYXOAH's last close was €6.80, 63.24% below its 52-week high of €18.50.

About NYXOAH

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Earnings Per Share

As for profitability, NYXOAH has a trailing twelve months EPS of €-0.68.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -23.22%.

Volume

Today's last reported volume for NYXOAH is 9473 which is 36.92% below its average volume of 15019.

Yearly Top and Bottom Value

NYXOAH's stock is valued at €6.80 at 14:43 EST, way under its 52-week high of €18.50 and way above its 52-week low of €4.45.

More news about NYXOAH (NYXH.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Sovereign, Local and Open AI: Infrastructure and Applied Intelligence Scale Up While Frontier-Lab Safety Scrutiny Grows
AI is shifting from cloud-rented models toward locally run, owned and open intelligence. ASUS/NVIDIA RTX Spark laptops pair with Nous Research's Hermes and ComfyUI, and Microsoft pushes hybrid local/cloud Windows. Cisco, NVIDIA and Marvell build open high-bandwidth AI infrastructure, and Hesai supplies real-world data for physical AI. In finance and commerce, Intuit, Zeta, Parloa/TELUS Digital and Snipp embed agentic AI into trusted financial and customer workflows, while OpenAI's math breakthroughs, its security disclosures and an executive's departure from its safety role keep safety and governance scrutiny high.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,397 source documents archived
Query this data → isubstrate.com